| Feb 27, 2026 |
Mar 3, 2026 |
Conroy Kevin T
|
CEO |
Sell |
40.0
|
-32,007
|
-0.78%
|
✗
|
$3.3M |
| Feb 27, 2026 |
Mar 3, 2026 |
Condella Sarah
|
EVP, Human Resources |
Sell |
42.5
|
-1,913
|
-1.37%
|
✗
|
$197.8K |
| Feb 25, 2026 |
Feb 27, 2026 |
Condella Sarah
|
EVP, Human Resources |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 25, 2026 |
Feb 27, 2026 |
Herriott James
|
SVP, General Counsel & Sec |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 25, 2026 |
Feb 27, 2026 |
Conroy Kevin T
|
CEO |
Sell |
67.5
|
+6,985
|
0.46%
|
✗
|
$641K |
| Feb 25, 2026 |
Feb 27, 2026 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 25, 2026 |
Feb 27, 2026 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 25, 2026 |
Feb 27, 2026 |
Bloomer Aaron
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 23, 2025 |
Dec 30, 2025 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Sell |
78.8
|
+4,086
|
0.51%
|
✗
|
$7M |
| Dec 23, 2025 |
Dec 30, 2025 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
88.8
|
+8,426
|
1.08%
|
✗
|
$8.6M |
| Dec 23, 2025 |
Dec 30, 2025 |
Condella Sarah
|
EVP, Human Resources |
Sell |
57.5
|
+80
|
0.01%
|
✗
|
$4.3M |
| Dec 23, 2025 |
Dec 30, 2025 |
Conroy Kevin T
|
CEO |
Sell |
95.0
|
+203,125
|
3.54%
|
✗
|
$34.2M |
| Dec 23, 2025 |
Dec 30, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
93.8
|
+22,450
|
4.21%
|
✗
|
$5.1M |
| Dec 23, 2025 |
Dec 30, 2025 |
Bloomer Aaron
|
CFO |
Sell |
37.5
|
-27,954
|
-24.93%
|
✗
|
$2.8M |
| Nov 19, 2025 |
Nov 21, 2025 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Sell |
17.5
|
-5,000
|
-16.82%
|
✓
|
$375K |
| Nov 19, 2025 |
Nov 21, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
32.5
|
-1,000
|
-7.07%
|
✓
|
$70K |
| Nov 4, 2025 |
Nov 6, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
28.8
|
-1,500
|
-9.59%
|
✓
|
$105.1K |
| Nov 4, 2025 |
Nov 6, 2025 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
25.0
|
-2,858
|
-11.04%
|
✓
|
$200.3K |
| Oct 24, 2025 |
Oct 27, 2025 |
Zanotti Katherine S
|
Director |
Sell |
17.5
|
-12,000
|
-16.49%
|
✓
|
$780K |
| Oct 9, 2025 |
Oct 10, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
28.8
|
-1,500
|
-8.75%
|
✓
|
$90K |
| Oct 9, 2025 |
Oct 10, 2025 |
Doyle James Edward
|
Director |
Sell |
37.5
|
-2,000
|
-3.34%
|
✓
|
$120K |
| Aug 13, 2025 |
Aug 14, 2025 |
Doyle James Edward
|
Director |
Sell |
41.3
|
-1,485
|
-2.42%
|
✓
|
$62.4K |
| Aug 5, 2025 |
Aug 7, 2025 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Sell |
42.5
|
-2,515
|
-7.80%
|
✗
|
$117.8K |
| Aug 5, 2025 |
Aug 7, 2025 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
42.5
|
-2,717
|
-9.50%
|
✗
|
$127.2K |
| Jun 12, 2025 |
Jun 16, 2025 |
Doyle James Edward
|
Director |
Neutral |
85.0
|
+5,398
|
9.63%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
Barber Michael J
|
Director |
Neutral |
90.0
|
+7,197
|
121.18%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
Clancy Paul J
|
Director |
Neutral |
90.0
|
+5,398
|
26.15%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
Popovits Kimberly J
|
Director |
Neutral |
90.0
|
+9,994
|
156.47%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
Trigg Leslie
|
Director |
Neutral |
90.0
|
+7,670
|
80.75%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
Petrovic Shacey
|
Director |
Neutral |
90.0
|
+5,398
|
22.97%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
Zanotti Katherine S
|
Director |
Sell |
87.5
|
+2,191
|
3.10%
|
✓
|
$170.6K |
| Jun 12, 2025 |
Jun 16, 2025 |
LEVANGIE DANIEL J
|
Director |
Neutral |
90.0
|
+5,398
|
18.67%
|
✗
|
- |
| Jun 12, 2025 |
Jun 16, 2025 |
COWARD D SCOTT
|
Director |
Neutral |
85.0
|
+5,398
|
9.49%
|
✗
|
- |
| Apr 30, 2025 |
May 8, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Neutral |
77.5
|
+363
|
2.16%
|
✗
|
- |
| Apr 29, 2025 |
May 1, 2025 |
Trigg Leslie
|
Director |
Neutral |
90.0
|
+8,527
|
877.26%
|
✗
|
- |
|
May 1, 2025 |
Trigg Leslie
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 14, 2024 |
Apr 29, 2025 |
Conroy Kevin T
|
CEO |
Neutral |
27.5
|
-74,599
|
-6.60%
|
✗
|
- |
| Oct 26, 2020 |
Apr 29, 2025 |
Conroy Kevin T
|
CEO |
Neutral |
27.5
|
-163,000
|
-20.60%
|
✗
|
- |
| May 6, 2019 |
Apr 29, 2025 |
Conroy Kevin T
|
CEO |
Neutral |
27.5
|
-50,723
|
-5.23%
|
✗
|
- |
| Apr 15, 2025 |
Apr 17, 2025 |
Bloomer Aaron
|
CFO |
Sell |
40.0
|
-10,837
|
-34.84%
|
✗
|
$479.5K |
| Mar 7, 2025 |
Mar 10, 2025 |
Conroy Kevin T
|
CEO |
Sell |
17.5
|
-48,929
|
-3.17%
|
✗
|
$2.3M |
| Feb 28, 2025 |
Mar 4, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
42.5
|
-2,006
|
-6.13%
|
✗
|
$95.9K |
| Feb 28, 2025 |
Mar 4, 2025 |
Conroy Kevin T
|
CEO |
Sell |
42.5
|
-18,947
|
-0.72%
|
✗
|
$906K |
| Feb 28, 2025 |
Mar 4, 2025 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
42.5
|
-4,913
|
-10.16%
|
✗
|
$234.9K |
| Feb 28, 2025 |
Mar 4, 2025 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Sell |
42.5
|
-4,547
|
-8.39%
|
✗
|
$217.4K |
| Feb 28, 2025 |
Mar 4, 2025 |
Condella Sarah
|
EVP, Human Resources |
Sell |
45.0
|
-4,693
|
-1.84%
|
✓
|
$174K |
| Feb 25, 2025 |
Feb 26, 2025 |
Condella Sarah
|
EVP, Human Resources |
Sell |
42.5
|
-1,859
|
-2.15%
|
✗
|
$95.3K |
| Feb 25, 2025 |
Feb 26, 2025 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
42.5
|
-2,008
|
-9.79%
|
✗
|
$103K |
| Feb 25, 2025 |
Feb 26, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
46.3
|
-775
|
-5.07%
|
✗
|
$39.7K |
| Feb 25, 2025 |
Feb 26, 2025 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Sell |
42.5
|
-1,859
|
-7.87%
|
✗
|
$95.3K |
| Feb 24, 2025 |
Feb 26, 2025 |
Bloomer Aaron
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 25, 2025 |
Feb 26, 2025 |
Conroy Kevin T
|
CEO |
Sell |
45.0
|
-6,195
|
-0.42%
|
✗
|
$317.7K |
| Feb 19, 2025 |
Feb 21, 2025 |
Conroy Kevin T
|
CEO |
Sell |
87.5
|
+23,633
|
1.66%
|
✗
|
$1.2M |
| Feb 19, 2025 |
Feb 21, 2025 |
COWARD D SCOTT
|
Director |
Sell |
46.3
|
-667
|
-1.16%
|
✗
|
$33.1K |
| Feb 19, 2025 |
Feb 21, 2025 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Sell |
90.0
|
+1,494
|
8.22%
|
✗
|
$166.2K |
| Feb 19, 2025 |
Feb 21, 2025 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
90.0
|
+1,400
|
9.24%
|
✗
|
$171.1K |
| Feb 19, 2025 |
Feb 21, 2025 |
Condella Sarah
|
EVP, Human Resources |
Sell |
82.5
|
+1,484
|
1.83%
|
✗
|
$166.7K |
| Feb 19, 2025 |
Feb 21, 2025 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
95.0
|
+1,360
|
11.07%
|
✗
|
$98.8K |
| Jan 2, 2025 |
Jan 6, 2025 |
Popovits Kimberly J
|
Director |
Neutral |
90.0
|
+6,387
|
100.00%
|
✗
|
- |
|
Jan 6, 2025 |
Popovits Kimberly J
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
Zanotti Katherine S
|
Director |
Neutral |
85.0
|
+5,939
|
9.19%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
LEVANGIE DANIEL J
|
Director |
Neutral |
90.0
|
+5,939
|
25.85%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
Petrovic Shacey
|
Director |
Neutral |
90.0
|
+5,939
|
56.74%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
Barber Michael J
|
Director |
Neutral |
90.0
|
+5,939
|
100.00%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
Doyle James Edward
|
Director |
Neutral |
90.0
|
+5,939
|
11.85%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
Clancy Paul J
|
Director |
Neutral |
90.0
|
+5,939
|
40.40%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
Sebelius Kathleen
|
Director |
Neutral |
90.0
|
+7,672
|
30.69%
|
✗
|
- |
| Jun 13, 2024 |
Dec 20, 2024 |
COWARD D SCOTT
|
Director |
Neutral |
90.0
|
+5,939
|
13.30%
|
✗
|
- |
| Nov 13, 2024 |
Nov 13, 2024 |
Conroy Kevin T
|
CEO |
Buy |
87.5
|
+19,500
|
1.40%
|
✗
|
$1M |
| Oct 8, 2024 |
Oct 9, 2024 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
32.5
|
-929
|
-6.57%
|
✓
|
$65K |
| Sep 18, 2024 |
Sep 19, 2024 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
32.5
|
-929
|
-6.16%
|
✓
|
$65K |
| Aug 5, 2024 |
Aug 6, 2024 |
Baranick Brian
|
EVP, GM, Precision Oncology |
Sell |
42.5
|
-1,375
|
-8.36%
|
✗
|
$76.7K |
| Aug 5, 2024 |
Aug 6, 2024 |
ORVILLE JACOB A
|
EVP, GM, Screening |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
Doyle James Edward
|
Director |
Neutral |
90.0
|
+5,444
|
10.86%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
Sebelius Kathleen
|
Director |
Neutral |
90.0
|
+6,889
|
27.56%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
Clancy Paul J
|
Director |
Neutral |
90.0
|
+5,444
|
37.03%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
Zanotti Katherine S
|
Director |
Neutral |
85.0
|
+5,444
|
8.42%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
LEVANGIE DANIEL J
|
Director |
Neutral |
90.0
|
+5,444
|
23.70%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
COWARD D SCOTT
|
Director |
Neutral |
90.0
|
+5,444
|
11.03%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
Petrovic Shacey
|
Director |
Neutral |
90.0
|
+5,444
|
31.00%
|
✗
|
- |
| Jun 13, 2024 |
Jun 17, 2024 |
Barber Michael J
|
Director |
Neutral |
90.0
|
+5,444
|
100.00%
|
✗
|
- |
|
Jun 17, 2024 |
Barber Michael J
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
May 20, 2024 |
Bloomer Aaron
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Apr 30, 2024 |
May 2, 2024 |
COWARD D SCOTT
|
Director |
Sell |
60.0
|
+151
|
0.31%
|
✓
|
$4K |
| Apr 30, 2024 |
May 2, 2024 |
Cunningham Everett
|
Chief Commercial Officer |
Sell |
77.5
|
+863
|
1.85%
|
✓
|
$8.2K |
| Apr 30, 2024 |
May 2, 2024 |
Herriott James
|
SVP, General Counsel & Sec |
Sell |
85.0
|
+741
|
7.19%
|
✓
|
$1.8K |
| Apr 30, 2024 |
May 2, 2024 |
Elliott Jeffrey Thomas
|
CFO |
Sell |
85.0
|
+862
|
6.89%
|
✓
|
$8.2K |
| Apr 30, 2024 |
May 2, 2024 |
Baranick Brian
|
EVP, GM., Precision Oncology |
Sell |
67.5
|
+108
|
0.79%
|
✓
|
$6.6K |
| Apr 30, 2024 |
May 2, 2024 |
Condella Sarah
|
EVP, Human Resources |
Sell |
77.5
|
+824
|
1.06%
|
✓
|
$6.1K |
| Apr 30, 2024 |
May 2, 2024 |
ORVILLE JACOB A
|
General Manager, Screening |
Sell |
67.5
|
+116
|
0.75%
|
✓
|
$6.1K |
| Apr 30, 2024 |
May 2, 2024 |
Conroy Kevin T
|
CEO |
Sell |
60.0
|
+2,042
|
0.15%
|
✓
|
$69.5K |
| Apr 1, 2024 |
Apr 3, 2024 |
Condella Sarah
|
EVP, Human Resources |
Sell |
41.3
|
-2,000
|
-2.52%
|
✓
|
$140K |
| Apr 2, 2024 |
Apr 3, 2024 |
Baranick Brian
|
EVP, GM., Precision Oncology |
Sell |
32.5
|
-924
|
-6.35%
|
✓
|
$73.4K |
| Mar 28, 2024 |
Apr 1, 2024 |
Condella Sarah
|
EVP, Human Resources |
Sell |
41.3
|
-2,000
|
-2.45%
|
✓
|
$140K |
| Feb 29, 2024 |
Mar 4, 2024 |
ORVILLE JACOB A
|
General Manager, Screening |
Sell |
25.0
|
-2,154
|
-12.24%
|
✓
|
$127.8K |
| Mar 1, 2024 |
Mar 4, 2024 |
LEVANGIE DANIEL J
|
Director |
Sell |
17.5
|
-5,000
|
-17.87%
|
✓
|
$287.5K |
| Feb 29, 2024 |
Mar 4, 2024 |
Herriott James
|
General Counsel |
Sell |
28.8
|
-862
|
-7.72%
|
✓
|
$51.1K |
| Feb 29, 2024 |
Mar 4, 2024 |
Elliott Jeffrey Thomas
|
CFO |
Sell |
20.0
|
-2,412
|
-16.16%
|
✓
|
$143.1K |
| Mar 1, 2024 |
Mar 4, 2024 |
Doyle James Edward
|
Director |
Sell |
37.5
|
-2,000
|
-3.84%
|
✓
|
$115K |
| Feb 29, 2024 |
Mar 4, 2024 |
Cunningham Everett
|
Chief Commercial Officer |
Sell |
37.5
|
-2,412
|
-4.91%
|
✓
|
$143.1K |